$ETST plans to raise an additional $1 million through its Regulation A+ offering, which it will use to complete further studies on its two pharmaceutical cannabidiol (CBD) based generic drugs, and for the completion of its three CBD formula provisional patents based on University of Central Oklahoma and DV Biologics studies.
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!